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SUPPRESSION OF NEOPLASTIC TRANSFORMATION IN VITRO BY LOW
DOSES OF LOW LET RADIATION
J. Leslie Redpath, PhD  Department of Radiation Oncology, UC Irvine, CA
 A major concern of exposure to low doses of radiation is the risk of cancer induction.
Epidemiologic data are rarely powerful enough to accurately discriminate this risk at doses
<10 cGy. In order to gain insight into events at these low doses, laboratory-based studies of
relevant endpoints are required. One such endpoint is radiation-induced neoplastic trans-
formation in vitro. Such studies can provide quantitative dose-response data, as well as
insights into underlying cellular and molecular mechanisms. Data are presented that indi-
cate that low doses of low LET radiation can suppress neoplastic transformation in vitro to
levels below that seen spontaneously. Mechanisms involved include both the death of a
subpopulation of cells prone to spontaneous neoplastic transformation and the induction
of DNA repair. The relative contributions of these mechanisms is dose-dependent. The rel-
evance of these observations to radiation risk estimation is discussed.
I. INTRODUCTION
The study of the effects of low doses of radiation has long been rec-
ognized to be of great importance to the understanding of potential risk
associated with such exposures. The gold standard with respect to esti-
mation of such risks continues to be epidemiologic studies of human pop-
ulations that have been exposed to radiation of one type or another.1, 2
Current regulations for radiation exposure are based on the fact that the
majority of epidemiologic data conform, within statistical confidence lim-
its, to a linear, no-threshold hypothesis. While epidemiologic studies are
clearly of value to the estimation of risk following relatively high dose
radiation exposure (e.g. >10 to 20 cGy), they are rarely sensitive enough
to accurately estimate risks at low doses (e.g. <10 cGy). Thus, laboratory-
based studies of low dose effects using relevant endpoints are required.
Until very recently there has been a paucity of such data, most likely for
the practical reason that low dose effects are difficult to measure.
However, the advent of the Low Dose Radiation Research Program spon-
sored by the U.S. Department of Energy has provided a stimulus for inves-
tigators to attempt such research. Laboratory studies can take two main
approaches. The first is to attempt to gain insight into possible molecular
and cellular events following such low doses that in turn may help predict
possible carcinogenic effects. The second is to actually attempt to per-
form quantitative dose-response studies in the low dose (<10 cGy) region.
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We have attempted to embrace both approaches using the endpoint of
neoplastic transformation in vitro.
II. ASSAY OF NEOPLASTIC TRANSFORMATION IN VITRO
Neoplastic transformation in vitro simply means the conversion of
cells in culture from a non-tumorigenic phenotype to a tumorigenic phe-
notype. Such phenotypes are identified by whether the cells will or will
not grow tumors following implantation into suitable host animals.
Quantitative studies of radiation effects using neoplastic transformation
as an endpoint have been performed for the last forty years. These stud-
ies have almost exclusively been carried out using various rodent cell lines
and at high radiation doses. They have been very useful in the examina-
tion of the effects of dose-rate, dose-fractionation, LET, and chemical
modifiers where they have shown clear relevance to carcinogenesis in
vivo.3 Ideally, since we are interested in radiation-induced human cancers,
principally carcinomas, such studies would be carried out using normal
human epithelial cells. Unfortunately, both normal and immortalized
human cells have proven to be extremely refractory to neoplastic trans-
formation in vitro.4 The only quantitative assay that is human cell-based is
the HeLa x skin fibroblast human hybrid cells assay developed in our lab-
oratory.5,6 In our opinion, this assay has several advantages over the more
widely used rodent cell-based assays. These are that the cells used are
human-derived, that the assay relies on a molecular marker of neoplastic
transformation rather than a change in morphology, that the mechanism
of transformation is known to involve the loss tumor suppressor genes on
chromosomes 11 and 147, and that the assay takes 21 to 24 days to com-
pletion compared to around 50 days for the often used mouse cell-based
C3H10T1/2 assay. This latter point is of significant practical advantage,
particularly for low dose assays that necessarily involve many culture dish-
es and several repeat experiments. On the other hand, it should be made
absolutely clear that these human hybrid cells are not normal cells. They
are transformed, i.e. they are immortal and do not exhibit contact-inhib-
ited growth. However, they are non-tumorigenic and as such should be
regarded as pre-neoplastic cells. The study of radiation effects on such
cells is nonetheless of importance since healthy humans harbor preneo-
plastic tissue.
III. THE SHAPE OF THE DOSE RESPONSE CURVE FOR 
NEOPLASTIC TRANSFORMATION FOLLOWING LOW 
DOSES OF LOW LET RADIATION
Azzam et al.,8 using a clone of C3H10T1/2 cells, demonstrated that
low doses of Co-60 gamma radiation could suppress transformation fre-
quencies to levels below that seen spontaneously. This observation stimu-
lated us to see if we could observe the same effect in the HeLa x skin
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fibroblast human hybrid cell system, which we subsequently did using Cs-
137 gamma radiation.9 It is important to note that both studies involved
a post-irradiation holding of cells at relatively high cell density for 24 h
prior to plating for the transformation assay. We then embarked on a
major endeavor to attempt to define the shape of the dose response
curve, encompassing several doses both below and above 10 cGy.10 The
data are shown in Fig. 1 and it can be seen that the dose-response curve
shows a tendency at low doses to deviate from the linear extrapolation
from high doses. Importantly, a similar phenomenon was subsequently
demonstrated for 60 kVp x-rays (see Fig. 2), an energy widely used in
diagnostic radiology.11 This suppression of transformation could be the
consequence of an adaptive response,12 classically thought of as the
induction of some sort of protective mechanism, e.g. DNA repair. This
induction takes some hours to maximize which could explain why we see
the suppressive effect more clearly with delayed plating. An alternative
explanation for the suppression could be the selective killing of a sub-
population of cells already destined to become neoplastically trans-
formed.13,14 Indeed, both of these mechanisms could be operative,
although with different dose dependencies, much along the lines of
hyper-radiosensitivity and induced-radioresistance described by Joiner
and colleagues,15 and supported by the recent observation that there
appears to be a threshold dose for DNA double-strand break repair to
come into play.16 Recent mechanistic studies from our own laboratory
would also support this concept.17 At the very lowest doses used (<0.1
cGy), not all cells experience an ionizing event, and bystander effects
18,19,20 may come into play. In summary, in this author’s opinion it is like-
ly that multiple mechanisms are involved and that their relative impor-
tance is dose-dependent.17
Fig. 1. Transformation frequency as a function of dose for Hela x skin fibroblast human
hybrid cells irradiated with Cs-137 gamma radiation.  Error bars represent 95%
confidence intervals. The straight line represents a linear regression through the high
dose points Data are for 24h post-irradiation plating
0
1
2
3
4
5
6
7
8
9
0 10 20 30 40 50 60 70 80 90 100
Dose (cGy)
T
r
a
n
sf
o
r
m
a
ti
o
n
 F
r
e
q
u
e
n
c
y
 (
x
1
0
  
5 )
FIGURE 1. Transformants per surviving cell as a function of dose for HeLa x skin fibroblast human
hybrid cells irradiated with Cs-137 gamma radiation. Error bars represent 95% confidence intervals.
The straight line rep esen s a linear regression through the high dose points (30, 50 and 100 cGy)
and the zero dos  point. Data are for 24h post-irradiation delayed plating. Reproduced from Ref. 10
with permissi n of the Radiati n Research Society.
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IV. RELEVANCE TO CANCER RISK IN HUMANS
The radiation-induction of cancer in humans is dependent on many
factors, both genetic and epigenetic, that are not possible to duplicate in
cells in vitro. A priori, therefore, one would not expect that studies of pre-
neoplastic cells in vitro to have a direct quantitative link to risk estimates
in human populations. It was, therefore, surprising to find that relative
risk estimates from our in vitro data agree surprisingly well with those for
the induction of breast cancer and leukemia in exposed humans at high
doses, say >10 to 20 cSv (see Ref. 10 and Fig. 3). Whether this is serendip-
itous or not, it nevertheless begs the question as to the relevance of our
low dose observations to the human situation. The in vitro data are strong-
ly suggestive of relative risks of <1 at low doses. There is evidence that sug-
gests that this could be the case for leukemia21, and in breast cancer it is
at the most very close to one.22-27 It should be stated that this epidemio-
logic data could equally well be fit by linear-quadratic functions and,
indeed, this is what is done for regulatory purposes. However, e.g. in case
of leukemia mortality, a best estimate of a threshold dose was 0.09 Sv,21 i.e.
close to what we determine in vitro. Taken together, these observations
indicate that the possibility of risks <1, or at the very least the possibility
of a threshold dose, must be taken seriously, at least for these tumors. On
the other hand, the latest epidemiologic analysis of all solid cancers in the
A-bomb survivors28 shows no evidence for a risk of <1 at the lowest doses
(<0.1 Sv), although the upper 95% confidence limit for a threshold is
either 0.06 Sv or 0.10 Sv, depending upon whether survivors beyond 3,000
m from the epicenter are omitted or not. It would be desirable if the solid
tumor analysis were feasible on an individual tumor basis in order to
remove any confounding of the data by combining tumor types with dif-
ferent responses. 
0
1
2
3
4
5
6
7
0 0.04 0.1 0.4 4 9 18 36
Dose (cGy)
T
ra
n
s
fo
rm
a
ti
o
n
 F
re
q
u
e
n
c
y
 (
x
 1
0
5
)
FIGURE 2. Dose-dependence for neoplastic transformation of HeLa x skin fibroblast human hybrid
cells by 60 kVp X-rays. Data are for 24h post-irradiation delayed plating. Error bars represent 95%
confidence intervals. Reproduced from Ref. 11 with permission of Taylor and Francis Ltd.
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It is of interest to speculate that those tumors for which there may be
a relative risk of <1, or a true threshold dose, may be the tumors that are
more readily inducible at high dose (e.g. breast and leukemia), i.e. where
the tissue at risk has more of a genetic predisposition to genomic insta-
bility. The rationale for this being that normal tissues that may be more
susceptible to carcinogenesis at high doses because they have a relatively
low level of endogenous protection, and thus may be the very tissues that
are more influenced by an induced increase in this protection at low
doses. Further laboratory studies with appropriate cell lines may be able
to address this question.
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